Search
Osimertinib
go.drugbank.com/drugs/DB09330ApprovedInvestigationalApproximately 10% of patients with NSCLC have a rapid and clinically effective response to EGFR-TKIs due to the presence of specific activating EGFR mutations within the tumour cells. … [A7927] More specifically, deletions around the LREA motif in exon 19 and exon 21 L858R point mutations are correlated with response to therapy.
Givosiran
go.drugbank.com/drugs/DB15066Approved[A187991] Givosiran is the second-ever FDA-approved member of the siRNA drug class (the first being [patisiran]), a new class of drugs promising an important and exciting step forward in the treatment … in which the overproduction of toxic heme intermediates leads to neuro-, nephro-, and gastrotoxicity.
Flecainide
go.drugbank.com/drugs/DB01195ApprovedInvestigationalWithdrawn[A186880] Flecainide’s development began in 1966 and was first synthesized in 1972 as an attempt to generate new anesthetics. … [A186931] It is used to prevent supraventricular and ventricular arrhythmias, as well as paroxysmal atrial fibrillation and flutter.
Sepiapterin
go.drugbank.com/drugs/DB16326ApprovedInvestigational[L53548,L53593] Sepiapterin was granted marketing authorization by the European Commission in June 2025 and by the US FDA in July 2025 for the treatment of adults and children with phenylketonuria. … It is a natural precursor of the enzymatic co-factor tetrahydrobiopterin (BH4), which activates PAH and helps reduce blood phenylalanine levels by enhancing the conformational stability of misfolded PAH
Antipyrine
go.drugbank.com/drugs/DB01435ApprovedAntipyrine is often used in testing the effects of other drugs or diseases on drug-metabolizing enzymes in the liver. (From Martindale, The Extra Pharmacopoeia, 30th ed, p29)
Edetate calcium disodium anhydrous
go.drugbank.com/drugs/DB14598ApprovedInvestigationalEdetate calcium disodium is a metal ion chelator used to reduce blood concentrations and depot stores of lead from the body. … [L12774] It is on the World Health Organization Model List of Essential Medicines.[A204173] Edetate calcium disodium was granted FDA approval on 16 July 1953.[L12774]
Products: Calcium Edetate de SodiumAlglucosidase alfa
go.drugbank.com/drugs/DB01272ApprovedInvestigationalAglucosidase alfa consists of the human enzyme acid alpha-glucosidase (GAA) which is essential for the degradation of glygogen to glucose in lysosomes. … It is used for the treatment of Pompe disease (GAA deficiency) in infants and pediatric patients.
Equine Botulinum Neurotoxin A Immune FAB2
go.drugbank.com/drugs/DB13900ApprovedIt is intravenously administered for the treatment of symptomatic botulism following documented or suspected exposure to botulinum neurotoxin serotypes A in adults and pediatric patients.
Pibrentasvir
go.drugbank.com/drugs/DB13878ApprovedInvestigationalThe ultimate goal of the combination treatment is to achieve sustained virologic response (SVR) and cure the patients from the infection. … In cell cultures, the emergence of amino acid substitutions at known NS5A inhibitor resistance-associated positions in HCV genotype 1a, 2a or 3a replicons led to reduced susceptibility and resistance to
Inulin
go.drugbank.com/drugs/DB00638ApprovedInvestigationalNutraceuticalA starch found in the tubers and roots of many plants. Since it is hydrolyzable to fructose, it is classified as a fructosan. … It has been used in physiologic investigation for determination of the rate of glomerular function.